MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today that it has completed patient enrollment in a Phase 2 trial for Gabapentin GR™ for the treatment of menopausal hot flashes. The company expects to report top-line results of this trial in the first quarter of 2008.
